-
Posted by
Two Blokes Jul 28 -
Filed in
Stock
-
2 views
Materialise's Q2 results were weak due to European automotive headwinds and macro uncertainty. Materialise's Medical segment continues to thrive, and its Software business is nearly done transitioning to a recurring revenue model. Medical segment strength justifies a higher valuation, but the Manufacturing business must stabilize before the stock can meaningfully re-rate.
